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ORIGINAL ARTICLE INFECTIOUS DISEASESRectal bacteriotherapy for recurrent Clostridium difﬁcile-associated
diarrhoea: results from a case series of 55 patients in Denmark 2000–2012M. Tvede, MD1, M. Tinggaard, MD2 and M. Helms, PhD3
1) Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, 2) Department of Pediatrics, Holbaek Hospital, Holbaek and
3) Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, DenmarkAbstractClostridium difﬁcile infection is one of the most common nosocomial infections. Among other alternatives to standard treatment with
vancomycin for recurrent infection are faecal microbiota transplantation and rectal bacteriotherapy with a ﬁxed mixture of intestinal
bacterial strains isolated from faeces of healthy persons to mimic a theoretical normal microﬂora. Developed by Dr. Tvede and Dr.
Rask-Madsen, the latter method has been in use for selected patients during the last 25 years in Denmark. In this study we reviewed the
medical records of patients treated with rectal bacteriotherapy for relapsing C. difﬁcile in Denmark, 2000–2012. The primary end point
was recurrent diarrhoea within 30 days after treatment. A total of 55 patients were included in this case series. Thirty-ﬁve patients
(64%) had no recurrence within 30 days of bacteriotherapy. Patients with recurrence tended to be older (75.8 years vs. 61.3 years; p
0.26), and more often have preexisting gastrointestinal illness and longer duration of time from the ﬁrst CDI to bacteriotherapy (221.6
days vs. 175.3 days; p 0.18). Treatment success was 80% in the subgroup of patients with no known gastrointestinal illness and ﬁrst C.
difﬁcile episode less than 6 months before bacteriotherapy. The most common adverse events were abdominal pain (10.9%) and
worsening diarrhoea (4.3%). One patient was hospitalized 10 days after treatment with appendicitis, fever, and Escherichia coli bacteremia.
The results from this study indicate that rectal bacteriotherapy is a viable alternative to faecal microbiota transplantation in patients with
relapsing C. difﬁcile-associated diarrhoea.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: mtvede@hotmail.comIntroductionToxigenic Clostridium difﬁcile was identiﬁed in 1976 by Larson
et al. as a cause of antibiotic-associated diarrhoea [1]. C. difﬁcile
infection (CDI) is now one of the most common nosocomial
infections and is associated with signiﬁcant economical burden
[2–6]. Infection ranges in severity from asymptomatic carriage
to pseudomembranous colitis, toxic megacolon, and death.Microbiol Infect 2015; 21: 48–53
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.07.003According to The European Society of Clinical Microbiology
and Infectious Diseases guidelines, ﬁrst-line treatment of
C. difﬁcile-associated diarrhoea includes either metronidazole or
vancomycin [7]. Recurrence rates are as high as 25% [3,8–10].
After the ﬁrst recurrence, the risk of subsequent recurrence
and chronic C. difﬁcile increases dramatically [3,11,12]. Risk
factors associated with recurrent CDI include advanced age,
immunosuppression, continued use of antibiotics after the ﬁrst
episode of C. difﬁcile, prolonged hospital stay, and antacid use
[13]. Treatment for a second or later recurrence includes a
tapered or long-term vancomycin. Due to high recurrence
rates and alteration of colonic microbiota with the continued
use of antimicrobial drugs, new approaches in therapy include
new narrow-spectrum antibiotics, probiotics, and monoclonal
antibodies [10,11,14,15].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Tvede et al. Rectal bacteriotherapy case series, Denmark 49Another way of treating recurrent C. difﬁcile that has
attracted much interest in recent years is by reintroducing
normal intestinal ﬂora by faecal microbiota transplatation (FMT)
using donor faeces, or by rectal bacteriotherapy (RBT) with a
ﬁxed mixture of commensal intestinal bacteria [16–19].
Restoring the normal colon microbiota was ﬁrst described
by Eiseman and coworkers in 1958 [20].
Results from case series [21–25] and a randomized clinical
trial [26] have shown success rates above 80% for faecal
transplantations. Despite administration of highly bacterially
active faecal matter, very few side effects have so far been re-
ported. Transfer of pathogens is, however, a risk to consider
when performing FMT.
In Denmark we have been using RBT with a ﬁxed mixture of
commensal intestinal bacteria for more than 200 patients dur-
ing the last 25 years [16]. In this article we report the results of
the case series of 55 patients treated with RBT in Denmark
during 2000–2012.Materials and methodsBacterial culture
Originally, the bacterial culture was composed of a mixture of
ten different facultatively aerobic and anaerobic bacteria. Lac-
tobacilIus rhamnosus and LactobacilIus acidophilus were added to
the mixture in the late 1990s, as they both demonstrated
positive effects on pathogens and a high adhesion to human
intestinal epithelium (Table 1) [27]. All the bacterial strains
were isolated from healthy persons, and except for the Bac-
teroides, sensitive to ampicillin. The Bacteroides sp. were chosen
as they are known to be a major part of commensal gut ﬂora
and were abscent in pretreatment stool samples from patients
in the original study [16]. The strains of Escherichia coli, Clos-
tridium bifermentans, and Peptostreptococcus productus in the
mixture were selected as they were shown to inhibit the in vitro
growth of C. difﬁcile, which in turn inhibited the growth ofTABLE 1. Composition of bacterial culture used for rectal
bacteriotherapy treatment in 55 patients with recurrent
Clostridium difﬁcile, Denmark 2000–2012
1. Bacteroides ovatus MT IS-la
2. Escherichia coli 1108 MT IS-Ib
3. E. coli 1109 MT IS-le
4. Streptococcus faecalis MT IS-Id
5. Lactobacillus sp MT IS-le
6. Bacteroides thetaiotaomicron MT IS-If
7. Bacteroides vulgatus MT IS-Ig
8. Clostridium bifermentans MT IS-Ih
9. Clostridium innocuum MT IS-2a
10. Clostridium ramosum MT IS-2b
11. LactobacilIus rhamnosus 19070-2
12. LactobacilIus acidophilus 18911-2
Bacterial concentration per species was approximately 1010/mL.
Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobioloBacteroides ovatus, Bacteroides vulgatus, and Bacteroides thetaio-
taomicron [16].
Preparation of the bacterial mixture
The strains were kept at −80.0°C in pure cultures. From these
stock cultures, the bacteria were cultured and a culture from
each strain was transferred to ﬂuid brain-heart infusion media.
After 24 hours of incubation in the anaerobic glove box at 37°C, a
sample from each of the ﬂuid media was cultured to quantify the
number of each strain in the media to secure that the speciﬁc
strain was alive and without contamination of other strains.
Immediately after, 4mL of each of the 12 cultureswas transferred
to a sterile ﬂask containing 152 mL sterile saline. Before adding
the cultures, the saline was treated in an anaerobic glovebox to
remove oxygen to secure survival of the anaerobes. The handling
of the preparation was carried out in a laboratory bench to avoid
contamination. After preparation the mixture was delivered to
the treating department and administered within 3 hours. A
control culture on the bacterial mixture was performed in order
to conﬁrm that all bacterial species were present at a concen-
tration of >109/mL.
Patient handling
Candidates for RBTwere patients with two ormore recurrences
of CDI veriﬁed by growth of C. difﬁcile in faeces cultured on
cycloserine cefoxitin fructose agar, and demonstration of toxin
by aMcCoy cell cytotoxic assay. Patients were treated for 7 to 10
days pre-RBT with vancomycin 500 mg four times daily. This
regime was the recommendation from some of the ﬁrst vanco-
mycin studies concerning treatment of C. difﬁcile in the late 1970s
[28]. The bacterial mixture was administered by either a baby
feeding tube or a suction catheter (CH10) introduced approxi-
mately 20 cm into the rectum. Patients were placed in Trende-
lenburg and side position with their knees bent during the
procedure and for 1 hour post infusion. Treatment was carried
out once daily on three consecutive days, either inpatient or
outpatient, depending on clinical condition and logistics.
Data collection
We examined medical records for patients using a predeﬁned
data entry form that included information on clinical outcome
and mortality up to 30 days after RBT. Treatment success was
deﬁned as clinical cure. A patient with a stool sample positive
for C. difﬁcile but no diarrhoea and no anti-clostridial treatment
was classiﬁed as a clinical success. Clinical failure was deﬁned as
recurrent diarrhoea where the physician in charge decided to
treat the patient for suspected or conﬁrmed C. difﬁcile. We also
collected information on initial CDI episode, prior hospitaliza-
tion, prior antimicrobial drug treatment for other reasons than
C. difﬁcile, and comorbidity [29].gy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 48–53
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All statistical analyses were performed in either Microsoft Excel
(Microsoft Corporation, Redmond, WA) or in SAS v 9.2 (SAS
Institute Inc., New York, NY).ResultsDuring the period January 1, 2000 to December 31, 2012, a
total of 58 patients with CDI were treated with RBT. We were
able to obtain detailed information for 55 patients during the
study period; three patient records could not be located.TABLE 2. Demographic and baseline clinical characteristics of 55 pa
rectal bacteriotherapy, Denmark 2000–2012
Patient
number Year Age, years Sex
Number of
comorbidity
conditions
K
g
il
1 2000 39 M 1 Y
2 2000 66 F 1 Y
3 2000 26 M 1 Y
4 2001 37 M 2 Y
5 2001 65 M 2 Y
6 2001 22 F 1 Y
7 2001 60 M 3 N
8 2001 79 F 1 N
9 2002 59 M 4 N
10 2002 83 M 2 N
11 2002 49 M 1 N
12 2002 66 M 1 Y
13 2003 28 F 0 N
14 2003 35 F 1 N
15 2003 42 M 1 N
16 2003 75 F 2 N
17 2003 77 M 3 N
18 2004 21 F 1 Y
19 2004 76 F 2 N
20 2005 36 F 0 N
21 2006 83 F 2 Y
22 2006 69 F 2 N
23 2006 52 F 1 N
24 2006 51 M 3 N
25 2006 81 F 3 Y
26 2006 67 F 2 N
27 2008 50 M 1 N
28 2008 73 M 3 N
29 2009 72 M 2 N
30 2009 54 F 2 Y
31 2009 93 M 1 N
32 2009 44 M 1 N
33 2010 62 F 2 Y
34 2010 78 F 3 N
35 2010 42 F 1 Y
36 2010 93 M 2 Y
37 2010 65 M 1 Y
38 2010 58 F 2 N
39 2011 91 F 1 N
40 2011 82 M 2 N
41 2011 68 F 2 Y
42 2011 61 F 1 N
43 2011 91 M 1 N
44 2011 80 F 2 N
45 2011 84 M 3 N
46 2011 70 F 0 N
47 2011 86 M 1 Y
48 2011 60 M 0 N
49 2011 84 F 1 N
50 2012 79 F 3 N
51 2012 78 F 2 N
52 2012 75 F 2 Y
53 2012 63 F 1 N
54 2012 61 M 3 N
55 2012 51 M 1 N
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectTwenty-nine (52.7%) patients were women. Median age was
65.6 years (range 21.1–93.1 years). RBT was performed at
eight different hospitals, and one patient was treated at a gen-
eral practioner’s ofﬁce.
Overall success rate was 63.6% (35 of 55 patients). Twenty
patients had a recurrence of CDIwithin 30 days of RBT (Table 2).
Median time to recurrence was 8 days (range 0–29 days). None
of the patients with recurrence of C. difﬁcile had any record of
antimicrobial drug use in the time from RBT until recurrence of
infection. Among patients with clinical recurrence, 15 (75%)
were microbiologically veriﬁed, three (15%) were with no posi-
tive samples, and two (10%) were of unknown microbiologicaltients with recurrent Clostridium difﬁcile infection treated with
nown
astrointestinal
lness
Days from ﬁrst
Clostridium
difﬁcile to RBT Outcome
Days to
recurrence
es 468 Success
es 88 Success
es — Success
es 33 Failure 8
es — Success
es 323 Failure 5
o 41 Success
o 85 Success
o 151 Success
o 372 Failure 25
o 154 Success
es 105 Failure 8
o 144 Success
o 299 Success
o 247 Success
o 231 Failure 2
o 155 Success
es — Failure 24
o 249 Failure 4
o 229 Failure 3
es 75 Failure 11
o 97 Failure 29
o 169 Success
o 113 Success
es 202 Failure 22
o 335 Failure 6
o 61 Success
o 74 Success
o 116 Success
es 180 Success
o 53 Success
o 175 Success
es 272 Success
o 305 Failure 0
es 364 Success
es 105 Success
es 230 Success
o 106 Failure 3
o 125 Failure 10
o 122 Success
es 532 Failure 15
o 123 Success
o 33 Failure 7
o 141 Failure 4
o 112 Success
o 97 Success
es 332 Failure 19
o 166 Success
o 179 Success
o 497 Success
o 385 Failure 23
es 137 Success
o 268 Success
o 216 Success
o 123 Success
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 48–53
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positive C. difﬁcile faecal sample within 30 days of RBT, but had no
clinical symptoms, and thus were not treated for CDI; they were
considered as a clinical success. Finally, ﬁve patients were treated
with RBT twice, three of whom were considered cured after the
second RBT. The last two patients had recurrence of illness
within 30 days of the second RBT treatment. Details on risk
factors and outcome is given in Table 3.
Information on complications was available for 46 (83.6%)
patients, and eight (17.4%) of these patients reported an adverse
event. There was no difference in the occurrence of adverse
events among patients with treatment success or failure.
Abdominal pain during or immediately after RBT was the most
common complaint (n = 5, 10.9%). Two (4.3%) patients reported
worsening of diarrhoea, and one patient was admitted to hospital
with appendicitis, fever, and an E. coli septicaemia. According to
the antibiogram data, both the E. coli causing the bacteremia and
the strains included in the RBT mixture were pan-susceptible,
except for the bacteremia isolate having reduced susceptibility
to mecillinam. No further comparison has been possible. The
patient was treated with ampicillin and gentamicin, recovered,
and had no recurrence of C. difﬁcile. There were no deaths within
the ﬁrst 30 days of RBT, but three deathswithin 90 days of follow-
up; one patient developed recurrent C. difﬁcile-associated diseaseTABLE 3. Risk factors and clinical outcome of 55 patients with
recurrent Clostridium difﬁcile infection treated with rectal
bacteriotherapy, Denmark 2000–2012
Treatment
pSuccess Failure
Age
Median, years (range) 61.3 (25.7–93.1) 75.8 (21.1–91.0) 0.26
Female, years (range) 62.8 (28.0–84.0) 75.1 (21.1–90.8) 0.52
Male, years (range) 60.4 (25.7–93.1) 83.0 (37.3–91.0) 0.25
Gender
Female, n (%) 14 (48.3%) 15 (51.7%) 0.01
Male, n (%) 21 (80.8%) 5 (19.2%)
Treatment as
Inpatient, n (%) 19 (61.3%) 12 (38.7%) 0.68
Outpatient, n (%) 16 (66.7%) 8 (33.3%)
Prior episodes of Clostridium difﬁcile
No. of episodes, mean (range) 4.1 (1–7) 4.3 (2–8) 0.77
Duration, mean (range), days 175.3 (41–497) 221.6 (33–532) 0.18
Time from ﬁrst episode to RBTa
< 180 days, n (%) 24 (75%) 8 (25%) 0.03
> 180 days, n (%) 9 (45%) 11 (55%)
Prior admission, any cause
Number (range) 3.7 (1–10) 4.4 (1–10) 0.43
Total admission time within
1 y before RBT, days
61.5 (1–173) 81.6 (8–261) 0.28
Prior antimicrobial drug treatment
No. of drugs, median (range) 4.6 (1–11) 4.4 (1–11) 0.81
Penicillins 18 (51.4%) 11 (55.0%) 0.38
Quinolones 17 (56.7%) 10 (66.7%) 0.52
Cephalosporins 15 (50.0%) 7 (46.7%) 0.83
Comorbidity
No. of comorbidities,
median (range)
1.6 (0–4) 1.7 (0–3) 0.70
Gastrointestinal comorbidityb 10 (28.6%) 8 (40.0%) 0.38
RBT, rectal bacteriotherapy.
aNumber of patients with valid information on date of ﬁrst episode = 52.
bGastrointestinal comorbidity: Irritable bowel syndrome, Crohn’s disease, ulcera-
tive colitis or chronic diarrhoea with prior negative C. difﬁcile stool sample.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolo47 days after RBI and died of severe C. difﬁcile-associated disease
on day 82. The other two patients died of pancreatic cancer and
cardiovascular illness.
Information on prior episodes of CDI with positive stool
samples for C. difﬁcile was available for 52 patients, while three
patients were treated with vancomycin on clinical suspicion. On
average, patients had four (range 1–8) prior episodes of
culture-conﬁrmed CDI (Table 3). In the 52 patients, median
time from ﬁrst episode to RBT was 154.5 days (range 33–532
days). Patients with treatment success tended to have shorter
mean time from ﬁrst episode of CDI to RBT (175.3 days; range
41–497 days) compared to patients with treatment failure
(221.6 days; range 33–532 days; p 0.18).
In order to explore this effect, patients were divided into
two groups of having less or more than 6 months from their
ﬁrst episode of CDI to RBT. Treatment success in patients with
less than a 6-month time interval was 75%, compared to 45% in
the group with ﬁrst episode more than 6 months prior to RBT
(crude p-value 0.03) (Table 3).
During the period from the ﬁrst episode of CDI and treatment
with RBT, patients received a median of four (range 1–11)
different antimicrobial drugs (Table 3). There was no difference in
number of different antimicrobials on outcome of RBT treatment.
Of the 55 patients in this study, 51 (92.3%) had one or more
preexisting illnesses, with a median of two (range 1–4)
comorbidities. Prior gastrointestinal illness was among the most
common preexisting condition (n = 18; 32.7%) (Table 3). Other
common comorbidity conditions were cardiovascular (36.4%),
pulmonary (27.3%), and renal disease (14.6%). No differences in
outcome were observed for the latter three groups.
Within 1 year before RBT, a total of 40 (72.7%) patients
were hospitalized, with a median of four (1–10) admissions and
a mean total number of 68.5 days (range 1–261 days) in the
hospital (Table 3).
Finally, we explored the possible effect of short versus long
duration of CDI before RBT. In a multivariate analysis con-
trolling for differences in age, gender, and gastrointestinal co-
morbidity, the risk of recurrence for patients with duration of
CDI for more than 6 months (n = 11; 55%) increased 2.7-fold
(95% CI 1.05–7.18) compared to patients with a history of
disease for less than 6 months (n = 8; 25%). In the subgroup of
patients with no known gastrointestinal illness and duration of
CDI less than 6 months prior to RBT, we found an 80% (20 of
25 patients) success rate (Fig. 1).DiscussionOnly very few studies have described the use of bacter-
iotherapy with a ﬁxed mixture of aerobic and anaerobicgy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 48–53
FIG. 1. Outcome for patients with relapsing Clostridium difﬁcile
treated with rectal bacteriotherapy (RBT), Denmark 2000–2012. The
ﬁgure shows time to relapse (days after RBT) for the subgroup of pa-
tients with no known prior gastrointestinal illness.
52 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIbacteria for restoration of normal large instestinal ﬂora in pa-
tients with chronic recurrent CDI [16,17]. The method
described in this case series is, to our knowledge, the only RBT
option that has been available for (routine) clinical use [16].
Our results show an overall success rate of 63.6%, which
conﬁrms the results of the original report of bacteriotherapy,
although the success rate in the current study is lower [16].
The difference might be explained by the higher number of
cases included in the current study and differences in risk fac-
tors among the study population. In the original report, none of
the treated patients suffered from gastrointestinal diseases
other than relapsing C. difﬁcile diarrhoea.
Reports from other studies support the theory that infusion
of fresh faeces or a mixture of bacteria can help restore in-
testinal ﬂora. In a recent study by Petrof et al. [17], adminis-
tration of a ﬁxed mixture of 33 isolates in two patients with
recurrent C. difﬁcile resulted in resolution of diarrhoea in both
patients. It has also been shown that a mixture of six intestinal
bacterial strains resolved CDI in mice [18]. Hamilton et al. [25]
have shown that a standardized frozen preparation of faecal
microbiota from a healthy donor could be used to clear
C. difﬁcile in three patients with recurrent CDI. A randomized
trial by van Nood et al. [26] including 43 patients concluded that
treatment of recurrent C. difﬁcile with infusion of donor faeces
through a nasoduodenal tube was signiﬁcantly more effective
than the use of vancomycin.
Further studies show cure rates above 80% with faecal
transplantation using fresh donor stools [21–24]. Results
should, however, be compared with caution, as most of the
studies, including ours, are case series of highly selected patients.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectOne concern with FMT is the risk of tranfer of pathogens in
spite of careful donor screening [17,30], and the risk of donor
faeces containing multiresistant strains and transferable resis-
tant factors. This risk of pathogen transfer is lowered signiﬁ-
cantly when a standardized mixture of known and antibiotic-
sensitive bacteria is used. Furthermore, the issue of aesthetics
has been much debated in association with faecal microbiota
transplantation. The same aspect does not to the same extent
apply to RBT mixture.
Most of the bacteriotherapy studies have used either colo-
noscopy, or nasogastric or duodenal tube [17,21–25] as means
of administration. The administration of the bacterial mixture
by our method is very “low tech” and cheap, using only either
baby feed tube or a tracheal suction catheter, and can be
performed in hospitals, outpatient clinics, and at the general
practioner’s ofﬁce (done in one patient in this case series).
FMTs are usually given as a single administration, whereas RBT
in this study was given as three consecutive administrations to
optimise results.
When given a large inoculum of live bacteria, there is always
a risk of bloodstream infection. In our case series, one patient
was admitted to hospital with acute onset of fever, signs of
appendicitis, and E. coli bacteremia 10 days after RBT. Except
for the antibiogram data that were identical for the antibiotics
tested, a further comparison between the E. coli strains was not
possible, and as more than half of E. coli isolates in Denmark are
sensitive to antibiotics like the E. coli strain found in this case, it
is not possible to judge whether or not the appendicitis was
caused by the RBT treatment or a mere event.
In all other RBT-treated patients, only few and mild adverse
events were noted.
Our study has limitations. Some data were difﬁcult to
retrieve from patient hospital records, in particular among
patients included early in the study period. Also, we have no
information allowing us to differentiate patients with recurrent
diarrhoea after RBT as either relapse or possible reinfection, as
we did not have any data on ribotypes of C. difﬁcile strains.
In order to conﬁrm the results from this case series and the
original study, and to further explore the effect of treatment in
patients with long versus short duration of CDI prior to RBT,
we are preparing a single(patient)-blinded randomized clinical
trial for patients with ﬁrst recurrence of C. difﬁcile randomly
treated with either RBT or placebo (physiological saline).
In conclusion, this case series shows an overall treatment
success in 64% of patients treated via RBT. In the subgroup of
patients with no known gastrointestinal illness and a duration of
CDI less than six months prior to RBT, we found an 80%
treatment success. The results indicate that RBT is a viable
alternative to faecal microbiota transplantation in patients withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 48–53
CMI Tvede et al. Rectal bacteriotherapy case series, Denmark 53relapsing C. difﬁcile-associated diarrhoea, but requires optimi-
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